Medicaid Expansion: Glass Half Full for Biopharma
This article was originally published in RPM Report
Most health reform watchers have been tracking state votes on Medicaid expansion as a sort of scorecard on whether Obama Administration is winning or losing in health care reform. Push back from the states is making news now, but for biopharma sponsors, even a glass half full is a positive—and the long-term outlook is even brighter.
You may also be interested in...
Implementation of the Affordable Care Act in 2014 will help significantly increase growth for pharma. The increase won’t be as big as it might have been, thanks to the Supreme Court ruling allowing states to opt out of Medicaid expansion, but it should still be a significant acceleration.
Visits from HHS Secretary Sebelius raise the question of whether Texas could change its mind and expand Medicaid eligibility under the ACA.
Express Scripts CEO says prescription drug utilization will be flat in the first year of Medicaid expansion and insurance exchanges. With millions of Americans expected to get health coverage in 2014, can that projection be true?